Sep 22, 2021 / 05:00PM GMT
Presentation Part 1: Transplant Rejection Testing
Sep 22, 2021 / 05:00PM GMT
=====================
Corporate Participants
=====================
* Ronald A. Andrews
OncoCyte Corporation - CEO, President & Director
* Sara Riordan
OncoCyte Corporation - Director of Medical Education
=====================
Conference Call Participants
=====================
* Bruce David Jackson
The Benchmark Company, LLC, Research Division - Senior Equity Analyst
* Mark Anthony Massaro
BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools Analyst
* Michael Stephen Matson
Needham & Company, LLC, Research Division - Senior Analyst
* Thomas Flaten
Lake Street Capital Markets, LLC, Research Division - Senior Research Analyst
* Ekkehard Schuetz
* Michael Oellerich
=====================
Sara Riordan - OncoCyte Corporation - Director of Medical Education
Good afternoon, and welcome to the Oncocyte KOL Event Series Part 1 on
OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot